Novartis’s psoriatic arthritis drug shows good efficacy

Novartis has announced new data showing Cosentyx (secukinumab) delivers sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) over three years – including patient-reported pain.

Cosentyx is the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate   three-year efficacy in patients with PsA, a life-long inflammatory disease that affects the skin and joints. Cosentyx is also the only IL-17A inhibitor indicated for ankylosing spondylitis (AS), PsA, and psoriasis Рthis is significant as up to eight in 10 patients diagnosed with PsA already have psoriasis.

“Joint pain severely impacts the lives of many people living with psoriatic arthritis. The knowledge that Cosentyx delivers lasting pain relief, reduces swelling and helps keep joints moving is important as it means it could help improve both patient overall quality of life and mobility,” said Vasant Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. “Cosentyx provides much-needed pain relief and also delivers high and long-lasting skin clearance for psoriasis, which the majority of people with psoriatic arthritis also suffer from.”

Novartis explained that using Matching-Adjusted Indirect Comparison (MAIC) presented at ACR show Cosentyx may improve the signs and symptoms of AS and PsA more than Humira (adalimumab). In a new MAIC for AS, the ASAS 20 response rates at Week 52 were higher for Cosentyx (74%) than for Humira (65%). Likewise, in the MAIC for PsA patients, ACR 20 response rates at Week 48 were higher for Cosentyx (72%) than for Humira (56%).

Following these MAIC analyses, Novartis plans to initiate new head-to-head clinical trials to directly compare Cosentyx versus Humira in patients with AS and PsA. These will include 850 patients and will be the first ever adequately powered head-to-head studies with biologic medicines to differentiate the effectiveness of treatment in these conditions.

To remind, the European Commission (EC) approved Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) a year ago.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s